Recent Updates to the Regence Group Medical Policy Manual

Search:

» Medical Policy

» Medicare Policy

» Medication Policy

» Dental Policy

» Clinical Position Statements

» Practice Guidelines

» Vendor Communications

» Uniform Glossary of Terms

» Washington State Health Technology Clinical Committee (HTCC) Assessments

Regence Medical Policy Update, November 1, 2018
Changes to Regence Medical Policies Announced
The Regence Group and its affiliated Plans use medical policies as guidelines for coverage decisions within the member’s written benefits. Below are summaries of recent changes to The Regence Group’s medical policies. The detailed policies and complete Medical Policy Manual are available online at www.regence.com. We have included the section and policy number for your convenience.

*Policy Name*	Summary of Policy or Change	*Section and* *Policy #*	*Coding / Implementation Change*	*PreAuthorization Change*
Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers	Changed policy title. Added circulating tumor/cell-free DNA to the investigational statement. Effective Date: December 1, 2018	Laboratory, Policy No. 46	N/A	N/A
Genetic Testing for Hereditary Breast and/or Ovarian Cancer and Li-Fraumeni Syndrome	Changed policy title. Added review of TP53 genetic testing. Effective Date: November 1, 2018	Genetic Testing, Policy No. 02	N/A	Updated policy title on preauth website.
Reproductive Carrier Screening for Genetic Diseases	Changed policy title. Effective Date: November 1, 2018	Genetic Testing, Policy No. 81	N/A	Updated policy title on preauth website.
Hyperbaric Oxygen Pressurization (HBOT)	Added to the list of medically necessary indications. Effective Date: November 1, 2018	Medicine, Policy No. 14	N/A	N/A
Lumbar Spinal Fusion	Updated policy criteria statements, specifically with regard to neurogenic claudication, and clinical tools as a measure of disability. Updated policy guidelines to clarify documentation required for submission to support policy criteria. Effective Date: November 1, 2018	Surgery, Policy No. 187	N/A	N/A
Myoelectric Prosthetic and Orthotic Components for the Upper Limb	Changing policy title. Adding investigational criteria for upper-limb prosthetic components with both sensor and myoelectric control and for myoelectric controlled upper-limb orthoses. Effective Date: October 1, 2018	Durable Medical Equipment, Policy No. 80	Adding code L6693 with preauth edit.	Adding code L6693 with preauth edit. Changing the policy title on the preauth website.
KRAS, NRAS, and BRAF Variant Analysis and MicroRNA Expression Testing for Colorectal Cancer	Changed policy title. Added microRNA expression testing to policy. Effective Date: October 1, 2018	Genetic Testing, Policy No. 13	Add new CPT code 0069U to this medical policy as part of the quarterly code updates.	N/A
Genetic and Molecular Diagnostic Testing	Added criteria to address review of a genetic panel test when the always investigational position of Evaluating the Utility of Genetic Panels (#64) does not apply. Effective Date: October 1, 2018	Genetic Testing, Policy No. 20	N/A	N/A
Evaluating the Utility of Genetic Panels	Added 12 new genetic panel tests to policy. Effective Date: October 1, 2018	Genetic Testing, Policy No. 64	N/A	N/A
Analysis of Proteomic and Metabolomic Patterns for Early Detection or Assessing Risk of Cancer	Changed policy title. Added clarification that policy includes testing for cancer risk. Effective Date: October 1, 2018	Laboratory, Policy No. 41	Add new CPT code 0067U to this medical policy as part of the quarterly code updates. Delete CPT codes 81500, 81503, and 0002U from this medical policy.	N/A
Urine Drug Testing for Substance Use and Pain Management	Removed 0020U from presumptive testing criterion as part of annual code set update process. Clarified definitive testing codes in not medically necessary criterion. Effective Date: October 1, 2018	Laboratory, Policy No. 68	Removed deleted CPT code 0020U as part of the quarterly code updates.	N/A
Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance	Changed policy title. Added urinary testing for colonic polyps to policy. Effective Date: October 1, 2018	Laboratory, Policy No. 72	Add code 0002U and continue the investigational edit on this code.	N/A
Molecular Testing in the Management of Pulmonary Nodules	New policy addressing proteomic and gene expression testing for lung nodules. Effective Date: October 1, 2018	Laboratory, Policy No. 73	Continue no edit on code 83520 (code not specific) and continue to review unlisted code 64999.	N/A
Intensity Modulated Radiotherapy (IMRT) of the Thorax	Changed policy to address partial breast irradiation with the same criteria as whole breast irradiation. Effective Date: October 1, 2018	Medicine, Policy No. 136	N/A	N/A
Intensity Modulated Radiotherapy (IMRT) of the Prostate	Defined adverse pathological findings in criterion II.A. using widely accepted definition. Effective Date: October 1, 2018	Medicine, Policy No. 137	N/A	N/A
Intensity Modulated Radiotherapy (IMRT) for Central Nervous System (CNS)	Changed policy title. Removing vertebral tumors from this policy, as they are addressed in other relevant IMRT policies. Effective Date: October 1, 2018	Medicine, Policy No. 147	N/A	Policy title updated on the PreAuth list
New and Emerging Medical Technologies and Procedures	Added new investigational medical technologies in accordance with the 4th quarter code update. Effective Date: October 1, 2018	Medicine, Policy No. 149	Added CPT codes 0062U, 0063U, 0068U to this medical policy as part of the quarterly code updates.	N/A
Endometrial Ablation	Updated criteria regarding hormonal therapy. Clarified documentation requirements. Effective Date: October 1, 2018	Surgery, Policy No. 01	N/A	N/A
Cosmetic and Reconstructive Surgery	Maintained services that are always cosmetic in Cosmetic and Reconstructive Surgery, Surgery 12. Separated services that could be potentially medically necessary into the following new individual policies: Panniculectomy, Surgery, Policy No. 12.01 Pectus Excavatum, Surgery, Policy No. 12.02 Ventral Hernia Repair, Surgery, Policy No. 12.03 Blepharoplasty and Brow Ptosis Repair, Surgery, Policy No. 12.05 Rhinoplasty, Surgery, Policy No. 12.28 Laser Treatment for Port Wine Stains, Surgery, Policy No. 12.34 Chemical Peels, Surgery, Policy No. 12.50 Note: The separation of these indications into individual policies did not result in a change to policy criteria intent. Effective Date: October 1, 2018	Surgery, Policy No.s: 12 12.01 (new) 12.02 (new) 12.03 (new) 12.05 (new) 12.28 (new) 12.34 (new) 12.50 (new)	CPT codes will be removed from SUR12 and added to the new separate cosmetic and reconstructive surgery medical policies as appropriate to their indication.	The preauth website will be updated to reflect the new separate cosmetic and reconstructive surgery medical policies as appropriate to their indication.
Percutaneous Angioplasty and Stenting of Veins	Added inferior vena cava syndrome to the medically necessary indications. Effective Date: October 1, 2018	Surgery, Policy No. 109	N/A	N/A
Intracardiac Ischemia Monitoring	New investigational policy addressing intracardiac ischemia monitoring. Effective Date: October 1, 2018	Surgery, Policy No. 208	Add CPT codes 33999 and 93799, and HCPCS code C9750 to this investigational medical policy.	N/A
Evaluating the Utility of Genetic Panels	Added 12 new investigational panels and removed 1 panel. Effective Date: September 1, 2018	Genetic Testing, Policy No. 64	N/A	Added code 81413 to preauth website for this medical policy.
Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancers and Thyroid Cancer	Expanding the scope of the policy to address other cancers including, but not limited to skin cancers in the region. Effective Date: September 1, 2018	Medicine, Policy No. 138	N/A	N/A
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy	Revised criteria related to the Karnofsky performance score requirements. Effective Date: September 1, 2018	Surgery, Policy No. 16	N/A	N/A
Implantable Bone Conduction and Bone-Anchored Hearing Aids	Adding audiology criteria for bilateral implantation. Effective Date: September 1, 2018	Surgery, Policy No. 121	N/A	N/A
Magnetic Resonance (MR) Guided Focused Ultrasound (MRgFUS) and High Intensity Focused Ultrasound (HIFU) Ablation	Updated policy criteria to state that Magnetic resonance (MR) guided focused ultrasound (MRgFUS) may be considered medically necessary for medicine-refractory essential tremors (clinical documentation must be submitted for review). Effective Date: September 1, 2018	Surgery, Policy No. 139	Removed investigational edit on code 0398T and added preauthorization requirement.	Added code 0398T to the preauth website for this medical policy.
Sepsis	New clinical position statement that defines sepsis based on professional organization guidelines and indicates the response and documentation expected. Effective Date: August 1, 2018	Clinical Position Statement, No. 03	N/A	N/A
BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy	Added resectable stage III melanoma to criteria. Effective Date: August 1, 2018	Genetic Testing, Policy No. 41	N/A	N/A
Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer	Slight modification to policy title.Updated criteria to allow testing in any individual with primary breast cancer, stage I, II, or III. Effective Date: August 1, 2018	Genetic Testing, Policy No. 42	N/A	Update title on the preauth website
Immunological Cellular Therapies and Gene Therapies	Updated policy title. Updated background information to clarify scope. Added note that LUXTURNA is not addressed by this policy; see Medication Policy Manual for therapies not addressed in this policy. Effective Date: August 1, 2018	Medicine, Policy No. 42	N/A	N/A
Cosmetic and Reconstructive Surgery	Added new criteria for rhinoplasty. Effective Date: August 1, 2018	Surgery, Policy No. 12	N/A	N/A
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy	Revised criteria regarding metastases to CNS. Effective Date: July 18, 2018	Surgery, Policy No. 16	N/A	N/A
Cooling Devices Used in the Home Setting	Clarified phrasing in criteria to include circulating and noncirculating to the active and passive descriptions, respectively. Effective Date: July 1, 2018	Durable Medical Equipment, Policy No. 07	N/A	N/A
Molecular Markers in Fine Needle Aspirates of the Thyroid	Updated medical necessity statement to include ThyroSeq®, ThyGenX®, and ThyraMIR when criteria are met. Effective Date: July 1, 2018	Genetic Testing, Policy No. 49	Remove investigational edit on codes 0018U and 0026U, and add preauth edit.	Add codes 0018U and 0026U to the preauth website.
Evaluating the Utility of Genetic Panels	Added two new investigational panels and removed 16 panels. Effective Date: July 1, 2018	Genetic Testing, Policy No. 64	Remove investigational denial from codes 81410 and 81411 with move to the new medical policy GT77.	N/A
Genetic Testing for Heritable Disorders of Connective Tissue	New policy addresses genetic testing for heritable disorders of connective tissue. Criteria for symptomatic individuals, and relatives of those with a known disorder describes when testing may be considered medically necessary. Policy Guidelines specify clinical documentation requirements. Effective Date: July 1, 2018	Genetic Testing, Policy No. 77	New policy adds codes 81405 an 81408 with a preauth edit. Codes 81410 and 81411 are added to this policy with no edit.	Add medical policy to the preauth website for codes 81405 and 81408.
Urine Drug Testing for Substance Use and Pain Management	Updated criteria to: Allow specific codes for presumptive and definitive testing when up to 15 units are billed per type of testing, per year Deny G0482 and G0483 as not medically necessary Effective Date: July 1, 2018	Laboratory, Policy No. 68	Limiting both presumptive and definitive testing to specific codes (five for presumptive; three for definitive), one code per date of service by the same or different provider, and 15 codes for each type of testing, per year.	N/A
Charged-Particle (Proton) Radiotherapy	Changed policy title. Changed to consider charged particle therapy such as proton beam therapy medically necessary for central nervous system tumors which extend to 10mm or less from the optic chiasm, brain stem, or cervical spinal cord and for reirradiation of head and neck and central nervous system tumors. Effective Date: July 1, 2018	Medicine, Policy No. 49	N/A	Update policy title on the preauth website.
Implantable Cardioverter Defibrillator	Added several new indications for transvenous ICD placement. Removed requirement for specific contraindications for a transvenous ICD to the subcutaneous ICD criteria. Effective Date: July 1, 2018	Surgery, Policy No. 17	N/A	N/A
Spinal Cord and Dorsal Root Ganglion Stimulation	Change to allow simultaneous preauthorization for temporary and permanent devices. No separate preauthorization is required. Effective Date: July 1, 2018	Surgery, Policy No. 45	N/A	N/A
Sacral Nerve Neuromodulation/ Stimulation for Pelvic Floor Dysfunction	Change policy title. Change criteria to allow simultaneous preauthorization for temporary and permanent devices. No separate preauthorization is required. Effective Date: July 1, 2018	Surgery, Policy No. 134	N/A	Change title of medical policy on preauth website.
Sacroiliac Joint Fusion	Use of minimally invasive titanium triangular implants to fuse or stabilize the sacroiliac joint may be considered medically necessary when criteria are met. Effective Date: July 1, 2018	Surgery, Policy No. 193	Remove investigational denial on code 27279.	N/A
Genetic Testing for CADASIL Syndrome	Removed requirement for other methods of testing prior to genetic testing. Effective Date: June 1, 2018	Genetic Testing, Policy No. 51	N/A	N/A
Chromosomal Microarray Analysis (CMA) for the Genetic Evaluation of Patients with Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, or Congenital Anomalies	Changed medical policy title. Revised criteria to exclude next-generation sequencing panels from this policy, as they will be addressed in other genetic testing policies. Effective Date: June 1, 2018	Genetic Testing, Policy No. 58	Deleted codes 81470 and 81471 from this medical policy and moved to GT20 and GT64.	Changed title of medical policy on the PreAuth website.
Evaluating the Utility of Genetic Panels	Added five new investigational panels and removed 15 panels. Effective Date: June 1, 2018	Genetic Testing, Policy No. 64	Added codes 81470 and 81471 to this medical policy and keep the preauth requirement.	Added codes 81470 and 81471 to this medical policy and keep the preauth requirement.
Urinary Tumor Markers for Bladder Cancer	New investigational policy addressing urinary tumor markers for bladder cancer. Effective Date: June 1, 2018	Laboratory, Policy No. 52	N/A	N/A
Percutaneous Vertebroplasty, Kyphoplasty, Sacroplasty, and Coccygeoplasty	Clarified medical necessity criterion, and added clarification of documentation required to review in the Policy Guidelines section. Effective Date: June 1, 2018	Surgery, Policy No. 107	N/A	N/A
Implantable Bone Conduction and Bone-Anchored Hearing Aids	Changed criteria for clarity and consistency between audiology policies. Updated referenced devices to current models. Effective Date: June 1, 2018	Surgery, Policy No. 121	N/A	N/A
The following is a list of recently archived policies:
Supplement to MCG™ Criteria for Adult Substance-Related Disorders, Inpatient and Residential Behavioral Health Level of Care		Archive Effective Date: November 1, 2018		Behavioral Health, Policy No. 23
Genetic Testing for Li-Fraumeni Syndrome		Archive Effective Date: November 1, 2018 NOTE: Criteria that was previously reviewed using GT82 was moved to GT02.		Genetic Testing, Policy No. 82
Percutaneous Tibial Nerve Stimulation		Archive Effective Date: October 1, 2018		Surgery, Policy No. 154
Breast Duct Endoscopy (Ductoscopy)		Archive Effective Date: June 1, 2018		Medicine, Policy No. 112
Endovascular Angioplasty and/or Stenting for Intracranial Arterial Disease (Atherosclerotic and Aneurysms)		Archive Effective Date: June 1, 2018		Surgery, Policy No. 141


	The Blue Cross and/or Blue Shield Plans comprising The Regence Group serve Idaho, Oregon, Utah and much of Washington state. The Regence Group and each of its affiliate Plans are independent licensees of the Blue Cross and Blue Shield Association.